Abstract
We previously reported that the PPARĪ³ agonist troglitazone (TRO) inhibits proliferation and induces apoptosis in human MCF-7 breast carcinoma cells. To understand the mechanisms of antiproliferative and pro-apoptotic effects of TRO, we screened a limited DNA array containing 23 genes involved in regulating either the cell cycle and/or apoptosis. Four of the 23 genes screened exhibited regulation by TRO, with growth arrest and DNA damage-inducible gene 45 (GADD45) being the most strongly upregulated. TRO induced GADD45 mRNA expression in a time- and dose-dependent manner. Depletion of GADD45 by siRNA abrogated TRO-induced apoptosis in MCF-7 cells demonstrating the physiological relevance of GADD45 upregulation. Signaling pathways mediating TRO-induced GADD45 were also investigated. Several mitogen-activated protein kinase (MAPK) pathways were involved in the induction of GADD45 by TRO. Inhibition of the c-jun N-terminal kinase MAPK pathway by SP600125 partially abolished TRO-induced GADD45 mRNA, and protein expression and apoptosis. In contrast, inhibition of the p38 MAPK pathway by SB203580, or through overexpression of a dominant-negative mutant of p38 MAPK, augmented GADD45 mRNA induction and GADD45 promoter activation as well as cell apoptosis by TRO. Blockade of the extracellular signal-regulated kinase MAPK pathway by PD98059 also enhanced TRO's effects on GADD45 and apoptosis. Two other PPARĪ³ agonists pioglitazone and rosiglitazone did not induce GADD45 expression. Our finding of GADD45 induction by TRO may provide a new insight concerning the mechanisms for TRO's antiproliferative and pro-apoptotic effects in breast cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Asou H, Verbeek W, Williamson E, Elstner E, Kubota T, Kamada N and Koeffler HP . (1999). Int. J. Oncol., 15, 1027ā1031.
Bae MA and Song BJ . (2003). Mol. Pharmacol., 63, 401ā408.
Begum NM, Nakashiro K, Kawamata H, Uchida D, Shintani S, Ikawa Y, Sato M and Hamakawa H . (2002). Int. J. Oncol., 20, 599ā605.
Bruemmer D, Yin F, Liu J, Berger JP, Sakai T, Blaschke F, Fleck E, Van Herle AJ, Forman BM and Law RE . (2003). Circ. Res., 93, 38ā47.
Carrier F, Georgel PT, Pourquier P, Blake M, Kontny HU, Antinore MJ, Gariboldi M, Myers TG, Weinstein JN, Pommier Y and Fornace Jr. AJ . (1999). Mol Cell Biol, 19, 1673ā1685.
Chang TH and Szabo E . (2000). Cancer Res., 60, 1129ā1138.
Chen C . (1998). Am. J. Health Syst. Pharm., 55, 905ā925.
Chen F, Zhang Z, Leonard SS and Shi X . (2001). Oncogene, 20, 3585ā3589.
Chen IT, Smith ML, O'Connor PM and Fornace Jr. AJ . (1995). Oncogene, 11, 1931ā1937.
Chitturi S and George J . (2002). Semin. Liver Dis., 22, 169ā183.
Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA and Chilton FH . (1999). Carcinogenesis, 20, 1905ā1911.
Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM and Singer S . (1999). Proc. Natl. Acad. Sci. USA, 96, 3951ā3956.
Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D and Koeffler HP . (1998). Proc. Natl. Acad. Sci. USA, 95, 8806ā8811.
Finkel T and Holbrook NJ . (2000). Nature, 408, 239ā247.
Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I and Horikoshi H . (1988). Diabetes, 37, 1549ā1558.
Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, Ishikawa A, Peabody T, Montag A, Simon MA and He TC . (2002). Clin. Cancer Res., 8, 1288ā1294.
Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S and Koeffler HP . (2000). Cancer Res., 60, 5494ā5498.
Huin C, Schohn H, Hatier R, Bentejac M, Antunes L, Plenat F, Bugaut M and Dauca M . (2002). Biol. Cell, 94, 15ā27.
Kearsey JM, Coates PJ, Prescott AR, Warbrick E and Hall PA . (1995). Oncogene, 11, 1675ā1683.
Kostrubsky VE, Sinclair JF, Ramachandran V, Venkataramanan R, Wen YH, Kindt E, Galchev V, Rose K, Sinz M and Strom SC . (2000). Drug Metab. Dispos., 28, 1192ā1197.
Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I and Koeffler HP . (1998). Cancer Res., 58, 3344ā3352.
Kultz D, Madhany S and Burg MB . (1998). J. Biol. Chem., 273, 13645ā13651.
Lowell BB . (1999). Cell, 99, 239ā242.
Mita H, Tsutsui J, Takekawa M, Witten EA and Saito H . (2002). Mol. Cell Biol., 22, 4544ā4555.
Mossner R, Schulz U, Kruger U, Middel P, Schinner S, Fuzesi L, Neumann C and Reich K . (2002). J. Invest. Dermatol., 119, 576ā582.
Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S and Spiegelman BM . (1998). Mol. Cell, 1, 465ā470.
Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H and Nakagama H . (2003). Gastroenterology, 124, 361ā367.
Otto C, Lehrke M and Goke B . (2002). Pharmacogenomics, 3, 99ā116.
Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM and Halperin JA . (2001). Cancer Res., 61, 6213ā6218.
Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ and Davis RJ . (1995). J. Biol. Chem., 270, 7420ā7426.
Rishi AK, Sun RJ, Gao Y, Hsu CK, Gerald TM, Saeed Sheikh M, Dawson MI, Reichert U, Shroot B, Fornace Jr. AJ, Brewer G and Fontana JA . (1999). Nucleic Acids Res., 27, 3111ā3119.
Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T and Nebreda AR . (1994). Cell, 78, 1027ā1037.
Rumi MA, Sato H, Ishihara S, Kawashima K, Hamamoto S, Kazumori H, Okuyama T, Fukuda R, Nagasue N and Kinoshita Y . (2001). Br. J. Cancer, 84, 1640ā1647.
Sakaue M, Adachi H and Jetten AM . (1999). Mol. Pharmacol, 55, 668ā676.
Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K, Dent P and Fisher PB . (2002). Proc. Natl. Acad. Sci. USA, 99, 10054ā10059.
Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C and Spiegelman BM . (1998). Nat. Med., 4, 1046ā1052.
Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM and Fornace Jr. AJ . (1994). Science, 266, 1376ā1380.
Spiegelman BM . (1998). Diabetes, 47, 507ā514.
Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y, Ui M and Tokumitsu Y . (1999). Biochem. Biophys. Res. Commun., 261, 833ā837.
Takahashi S, Saito S, Ohtani N and Sakai T . (2001). Cancer Res., 61, 1187ā1195.
Takashima T, Fujiwara Y, Higuchi K, Arakawa T, Yano Y, Hasuma T and Otani S . (2001). Int. J. Oncol., 19, 465ā471.
Takekawa M and Saito H . (1998). Cell, 95, 521ā530.
Tong T, Fan W, Zhao H, Jin S, Fan F, Blanck P, Alomo I, Rajasekaran B, Liu Y, Holbrook NJ and Zhan Q . (2001). Exp. Cell Res., 269, 64ā72.
Wang X, Gorospe M and Holbrook NJ . (1999). J. Biol. Chem., 274, 29599ā29602.
Yang WL and Frucht H . (2001). Carcinogenesis, 22, 1379ā1383.
Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, Van Herle AJ and Law RE . (2001). Biochem. Biophys. Res. Commun., 286, 916ā922.
Yoshizawa K, Cioca DP, Kawa S, Tanaka E and Kiyosawa K . (2002). Cancer, 95, 2243ā2251.
Acknowledgements
This work was supported in part by the contributions of CALVIN DAKS DDS and Emily Chang. Florian Blaschke was supported by a research fellowship from Philipp Morris Incorporated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yin, F., Bruemmer, D., Blaschke, F. et al. Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene 23, 4614ā4623 (2004). https://doi.org/10.1038/sj.onc.1207598
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207598
Keywords
This article is cited by
-
Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms
Biological Trace Element Research (2023)
-
MAPK signaling pathway-targeted marine compounds in cancer therapy
Journal of Cancer Research and Clinical Oncology (2021)
-
CB13, a novel PPARĪ³ ligand, overcomes radio-resistance via ROS generation and ER stress in human non-small cell lung cancer
Cell Death & Disease (2020)
-
In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer
Journal of Experimental & Clinical Cancer Research (2017)
-
Rosiglitazone Suppresses Glioma Cell Growth and Cell Cycle by Blocking the Transforming Growth Factor-Beta Mediated Pathway
Neurochemical Research (2012)